GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Debt-to-EBITDA

China National Accord Medicines (SZSE:000028) Debt-to-EBITDA : 2.69 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

China National Accord Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥4,867 Mil. China National Accord Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,642 Mil. China National Accord Medicines's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥2,420 Mil. China National Accord Medicines's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.69.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China National Accord Medicines's Debt-to-EBITDA or its related term are showing as below:

SZSE:000028' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.82   Med: 1.1   Max: 2.42
Current: 2.42

During the past 13 years, the highest Debt-to-EBITDA Ratio of China National Accord Medicines was 2.42. The lowest was 0.82. And the median was 1.10.

SZSE:000028's Debt-to-EBITDA is ranked worse than
53.95% of 76 companies
in the Medical Distribution industry
Industry Median: 2.1 vs SZSE:000028: 2.42

China National Accord Medicines Debt-to-EBITDA Historical Data

The historical data trend for China National Accord Medicines's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Debt-to-EBITDA Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 1.06 1.20 0.91 1.23

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 2.08 2.80 1.77 2.69

Competitive Comparison of China National Accord Medicines's Debt-to-EBITDA

For the Medical Distribution subindustry, China National Accord Medicines's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's Debt-to-EBITDA falls into.



China National Accord Medicines Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China National Accord Medicines's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3632.005 + 1451.788) / 4147.263
=1.23

China National Accord Medicines's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4867.44 + 1642.184) / 2419.984
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


China National Accord Medicines  (SZSE:000028) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


China National Accord Medicines Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines